SAL0167 is an internally developed cyclic peptide program for hyperlipidemia that received NMPA clinical trial authorization in 2026. Authorization is not treated as evidence of actual dosing.
Mainland ChinaFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
473 matching companiesShowing 25–48 / 473
The website lists oral cyclic peptides NGA-101 (IL-4Rα), NGA-102 (TL1A), and NGA-103 (TSLP). Pipeline stage graphics cannot be verified through text extraction alone.
Mainland ChinaFull profile →
The MO-PION oral macromolecule platform website explicitly lists semaglutide, heparin, and micafungin applications. Micafungin provides a lead for cyclic peptide applications.
Mainland ChinaFull profile →
The website explicitly identifies an ORALINK oral α4β7 cyclic peptide co-development program with D&D at lead optimization, recorded separately from radiopharmaceutical / conjugate programs.
South KoreaFull profile →
ORALINK combines ligand conjugation, lipidation, and excipient strategies. The α4β7 cyclic peptide program with QIC is in lead optimization; its GLP-1 human evidence does not transfer to cyclic peptides.
South KoreaFull profile →
Signed a next-generation oral peptide co-development agreement with D&D explicitly including macrocyclic peptides. Its role is AI design; independent ownership of a disclosed clinical drug has not been established.
South KoreaFull profile →
The company disclosed a patent for an oral semaglutide nanoparticle formulation. This is a noncyclic peptide delivery reference, not clinical validation for cyclic peptides.
South KoreaFull profile →
The website separately describes H1K, an oral anti-obesity candidate, and ESAIDD cyclic peptide discovery. This review could not confirm that H1K is cyclic or has human results.
South KoreaFull profile →
Co-commercializes approved LINZESS and holds regional rights, alongside oral peptide discovery through Nimble. ABBV-859 is in Phase 1; its exact structure and mapping to Nimble assets remain unconfirmed.
United StatesFull profile →
On 2026-10-22, the company announced a proposed acquisition of PepStar's HCXT-2001 oral macrocyclic peptide program. Its Q3 announcement confirms Phase 1; closing conditions remain outstanding.
United StatesFull profile →
Counterparty for the HCXT-2001 transaction. Its role is recorded separately from Gilead's; the shared candidate is not counted as two independent drugs. The relationship between the Chinese sponsor and English legal entity requires confirmation.
Hong Kong, ChinaFull profile →
Uses AI to design oral IL-17A/F inhibitors. The company describes fully synthetic, compact cyclic peptidomimetics containing nonnatural amino acids.
IsraelFull profile →
A September 2026 company announcement states that an unnamed MSD candidate using its oral technology entered Phase 1. The candidate structure is not disclosed, so it cannot be classified as a cyclic peptide.
AustriaFull profile →
Soteria provides protective excipients, Phloral provides targeted release, and UTAC provides active transport of macromolecules. Cyclic peptide applications require separate validation.
United KingdomFull profile →
The Novo collaboration uses gastrointestinal tissue screening and formulation platforms to develop oral biologics. Specific drugs and cyclic peptide structures have not been disclosed.
United StatesFull profile →
Peptelligence previously conducted feasibility studies with Ferring to convert injectable peptides into oral formulations. It is retained as a historical delivery approach; current operations and ownership require verification.
United StatesFull profile →
EB613 is oral PTH(1-34), with disclosed clinical results and new-formulation bridging data and a planned Phase 3 program. Human evidence for this linear peptide is used only as a platform reference.
IsraelFull profile →
RaniPill is a swallowable robotic capsule. RT-101 octreotide is a historical human development program whose current activity is unconfirmed, recorded separately from conventional intestinal permeation enhancement.
United StatesFull profile →
NEORAL cyclosporine is a classic benchmark for oral cyclic peptides and microemulsion preconcentrates; it should not be assumed bioequivalent to Sandimmune.
SwitzerlandFull profile →
LINZESS (linaclotide) is an oral peptide with multiple disulfide bonds and a GC-C agonist acting locally in the gastrointestinal tract. Systemic bioavailability is not the primary success criterion.
United StatesFull profile →
TRULANCE (plecanatide) is an oral disulfide-constrained peptide and GC-C agonist acting locally in the gastrointestinal tract. Regional status is based on the Canadian product monograph reviewed.
Canada / United StatesFull profile →
Swallowed DDAVP desmopressin tablets are a classic oral disulfide peptide reference. Swallowed, orally disintegrating, and sublingual products should be recorded separately.
SwitzerlandFull profile →
Collaborates with Biogen to discover and optimize oral macrocyclic peptides for immune diseases. Named targets, candidates, and human results have not been disclosed.
CanadaFull profile →
Industry partner for Dayra's oral macrocyclic peptide collaboration, responsible for subsequent development and potential commercialization. Its role is recorded separately from Dayra's using a shared program identifier.
United StatesFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.